This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
TORONTO, June 25, 2013 (GLOBE NEWSWIRE) --
Polydex Pharmaceuticals Limited (Pink Sheets:POLXF) (the "Company") has updated the company website at
www.Polydex.com with an aim to provide greater transparency and other helpful information to shareholders, investors and interested parties alike.
The company's new website includes greater access to financial reports, recent news releases and company information as it becomes available, and includes links to current stock quotes and charts. Shareholders and visitors can also subscribe to receive News Releases directly from the Company website.
Information on the company's product line is available at
Polydex Pharmaceuticals Limited, based in Toronto, Ontario, Canada, is engaged in the development, manufacture and marketing of biotechnology-based products for the human pharmaceutical market, and also manufactures bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry.
Note: This press release may contain forward-looking statements, within the meaning of the United States Securities Act of 1933, as amended, and the United States Securities Exchange Act of 1934, as amended, regarding Polydex Pharmaceuticals Limited, including, without limitation, statements regarding expectations about future revenues or business opportunities or potential research projects. These statements are typically identified by use of words like "may", "could", "might", "expect", "anticipate", "believe", or similar words. Actual events or results may differ materially from the Company's expectations, which are subject to a number of known and unknown risks and uncertainties including but not limited to changing market conditions, future actions by the United States Food and Drug Administration or equivalent foreign regulatory authorities as results of pending or future clinical trials. Other risk factors discussed in the Company's quarterly reports may also affect the actual results achieved by the Company.
CONTACT: Investor Relations: North Arm Capital Services,
Linda Hughes, 1-877-945-1621, (Linda@northarm.com)